CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

The board (the "**Board**") of directors (the "**Director(s)**") of CANbridge Pharmaceuticals Inc. (the "**Company**") is pleased to announce the audited consolidated annual results of the Company and its subsidiaries (the "**Group**", "**we**", "**our**" or "**us**") for the year ended December 31, 2025 (the "**Reporting Period**"), together with comparative figures for the year ended December 31, 2024 as follows. These consolidated financial statements of the Group for the Reporting Period have been reviewed by the audit committee of the Board (the "**Audit Committee**") and audited by the Company's auditors, HLB Hodgson Impey Cheng Limited ("**HLB**").

In this announcement, "CANbridge", "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments, or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding.

BUSINESS HIGHLIGHTS

The Group has made significant progress with respect to its drug pipeline and business operations, including the following milestones and achievements:

Strategic cooperation with Baheal Medical. In August 2025, we began our strategic cooperation with Qingdao Baheal Medical INC. (青島百洋醫藥股份有限公司) a company listed on the Shenzhen Stock Exchange (Stock Code: 301015) ("**Baheal Medical**") pursuant to which (i) we appointed certain subsidiar(ies) of Baheal Medical as our exclusive Contract Sales Organization ("**CSO**") for the marketing service, and, if requested by such subsidiar(ies) of Baheal Medical, as the sole distributor, for Hunterase®, Livmarli® and Gaurunning® in mainland China, Hong Kong, and Macau (the "**Designated Regions**"), from which we received a strategic cooperation fee of RMB50 million; and (ii) a subsidiary of Baheal Medical subscribed 74,971,468 shares in our Company, under which we received a total consideration of approximately HK$100 million. At the end of 2025, we completed the transfer of

promotion and distribution arrangements to Baheal, ensuring continuity and efficiency in our operational processes. CANbridge and Baheal teams continue to work collaboratively on national-level market access for all three products in mainland China. Meanwhile, in Taiwan and Hong Kong, CANbridge team is making progress toward enlisting Livmarli® and Hunterase® into the local reimbursement formularies.

Hunterase® (idursulfase beta, formerly known as CAN101), an enzyme replacement therapy (ERT) for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. MPS II is number 73 in the "First National List of Rare Diseases" in China published in May 2018.

- CANbridge commercially launched Hunterase® in China in May 2021 in a non-reimbursed market. Patient identification has accelerated since launch, with 893 patients identified as of December 31, 2025. As of December 31, 2025, we have implemented commercial insurance programs (Huiminbao) in 142 cities, covering a population of 626 million in China.

Livmarli® (maralixibat oral solution, formerly known as CAN108), an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT) that is under development to treat rare cholestatic liver diseases including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). CANbridge has the exclusive rights to develop, commercialize, and under certain conditions, manufacture Livmarli® in Greater China. ALGS is number 5 in the "Second National List of Rare Diseases" in China published in September 2023.

- CANbridge commercially launched Livmarli® in China in January 2024 in a non-reimbursed market. Patient identification has accelerated since launch, with 900 ALGS patients identified as of December 31, 2025. As of December 31, 2025, we have implemented commercial insurance programs (Huiminbao) in 39 cities, covering a population of 260 million in China.

- In May 2024, Livmarli® was granted an expanded label by the National Medical Products Administration of China ("**NMPA**"). This approval extends the use of Livmarli® for the treatment of cholestatic pruritus in patients with ALGS to include those aged three months and older.

Gaurunning® (velaglucerase-beta for injection, formerly known as CAN103), an ERT for the treatment of Gaucher Disease (GD). GD is number 31 in the "First National List of Rare Diseases" in China published in May 2018.

- In March 2025, we announced that Gaurunning®, with its wholly - owned subsidiary, CANbridge (Shanghai) Life Sciences Ltd. as the holder, successfully passed the pre-approval inspection and pre-marketing GMP compliance inspection for the pilot biological product of divided manufacturing. Gaurunning® was the first innovative biological product in China to pass the inspection of divided manufacturing of biological products.

- In May 2025, we announced marketing approval of Gaurunning®, a class 1 new drug for treating type I and III Gaucher disease, in China.

- In December 2025, we announced inclusion of Gaurunning® (Velaglucerase-beta for Injection), a class 1 innovative drug, in China's first commercial health insurance innovative drug list.

Gene Therapy, a CANbridge-developed area of excellence, is a therapeutic modality that includes adeno-associated virus (AAV) as a gene delivery vehicle due to its potential to be a one-time, durable treatment for many genetic diseases. Duchenne Muscular Dystrophy (DMD, the most common form of progressive muscular dystrophy) is number 98 in the "First National List of Rare Diseases" in China published in May 2018.

- As of December 31, 2025, we have licensed a dual vector technology called "StitchR" from ScriptR Global for its application towards DMD. The StitchR technology enables delivery of larger gene payloads via two independent AAVs and is the basis for our DMD gene therapy program, which is currently in the research discovery stage. As of December 31, 2025, we have internally generated the proof-of-concept data for DMD pre-clinical studies. CANbridge is seeking to generate further data in large animal models, with a view to ultimately advance in human studies.

Organizational Updates:

- With effect from June 25, 2025, Dr. Fangxin Li has resigned as a non-executive Director and a member of the remuneration committee of the Board (the "**Remuneration Committee**").

- With effect from June 30, 2025, Ms. Zhao Wei has been appointed as a non-executive Director and a member of the Remuneration Committee. Ms. Zhao received her bachelor's degree of science with a major in business and finance in English from Shanghai Jiao Tong University in July 2001 and a master's degree of business administration from The University of Hong Kong in November 2013. Ms. Zhao is a non-practising member of the Chinese Institute of Certified Public Accountants. She is currently the managing director, Corporate Development and Investments of WuXi AppTec (Shanghai) Co., Ltd., and she is mainly responsible for sourcing, evaluating, executing and integrating its strategic acquisitions, investments and joint ventures. Ms. Zhao worked at Ernst & Young Hua Ming Shanghai Branch ("**EY Shanghai**") from September 2001 to April 2008. From February 2006 to April 2006, she briefly left EY Shanghai and worked for Deloitte & Touche Corporation Finance Ltd. Later, from May 2008 to November 2014, she worked at Ernst & Young (China) Advisory Limited. From March 20, 2019 to June 11, 2025, Ms. Zhao was a non-executive director of Clarity Medical Group Holding Limited (stock code 1406). From March 16, 2022 to October 12, 2023, Ms. Zhao was a non-executive director of Hua Medicine (stock code: 2552).

- With effect from June 30, 2025, Dr. Richard James Gregory has resigned as a member of the nomination and corporate governance committee of the Company (the "**Nomination and Corporate Governance Committee**").

- With effect from June 30, 2025, Dr. Lan Hu has been appointed as a member of the Nomination and Corporate Governance Committee.

- With effect from August 27, 2025, Mr. Wang Tingwei has been appointed as a non-executive Director and a member of the Nomination and Corporate Governance Committee. Mr. Wang received his master's degree in business administration from Peking University in 2011. Mr. Wang previously worked at Searainbow Enterprise (Holdings) Co., Ltd. (now renamed as China Reform Health Mgmt&Ser Grp Co Ltd.), Thomson Reuters Group, Shanghai GBI Investment Management Consulting Co., Ltd. (GBI). Mr. Wang joined Baheal Pharmaceutical Group Co., Ltd. in April 2016 and has served as director of business development for Baheal Intelligent Technology Group Co., Ltd., director of business development and vice president of Baheal Pharmaceutical Group Co., Ltd. Since December 2021, he has served as deputy general manager of Qingdao Baheal Medical INC., and concurrently as director of Baheal Wellness Industry International Trading Limited.

FINANCIAL HIGHLIGHTS

- Our revenue decreased by RMB35.1 million or 41.2%, from RMB85.1 million for the year ended December 31, 2024 to RMB50.0 million for the year ended December 31, 2025, which was primarily due to the cessation of Nerlynx® sales in Taiwan following the expiry of Nerlynx® distribution agreement at the end of 2024, as originally planned by the Company in 2021 for strategically focusing on rare disease. Excluding the Nerlynx® sales in Taiwan, our revenue increased by RMB9.0 million, or 22.0% as compared with the same period in 2024, which was mainly attributable to Gaurunning® sales initiation in the second half of 2025.

- Our other income and gains increased by approximately RMB115.2 million, turning from a loss of RMB5.5 million for the year ended December 31, 2024 to a profit of RMB109.7 million for the year ended December 31, 2025, primarily due to a gain of RMB101.0 million arising from the US lease termination. The gain arose as the tenant, a wholly-owned subsidiary of the Company, and the US lease property's landlord entered into a termination agreement to early terminate the lease related to the US leased property on February 24, 2025 with effect from February 28, 2025. Since the right-of-use assets related to the US lease property had been fully written off as of December 31, 2024, the lease liabilities and other payables of approximately RMB97.7 million and RMB3.3 million, respectively, were derecognised and credited to profit or loss during the year ended December 31, 2025.

- Our research and development expenses decreased by approximately RMB206.7 million or 82.1%, from RMB251.8 million for the year ended December 31, 2024 to RMB45.1 million for the year ended December 31, 2025, which was mainly attributable to the NDA approval of Gaurunning® in the first half of 2025, resulting in a substantial reduction in related development activities and expenditures.

- Our administrative expenses decreased by RMB31.4 million or 46.0%, from RMB68.2 million for the year ended December 31, 2024 to RMB36.8 million for the year ended December 31, 2025. Such decrease was primarily attributable to our efforts on the containment of employee costs and other administrative costs during the Reporting Period.

- Our selling and distribution expenses decreased by approximately RMB27.5 million or 36.7%, from RMB74.9 million for the year ended December 31, 2024 to RMB47.4 million for the year ended December 31, 2025. The decrease was mainly due to the elimination of Nerlynx® sales activities and related employee costs in 2025, following the termination of its distribution agreement at the end of 2024, coupled with an increase in the sales effectiveness for rare disease products during the Reporting Period.

- Profit for the Reporting Period increased by approximately RMB457.4 million, turning from a loss of RMB442.6 million for the year ended December 31, 2024 to a profit of RMB14.8 million for the year ended December 31, 2025, which was primarily attributable to the increase of other income and gains and decrease of selling and distribution expenses, R&D expenses, and administrative expenses, and partially offset by a decline in revenue. The profit of RMB14.8 million is not due to the ordinary business and operations of the company and is non-recurring.

- The adjusted loss for the period decreased by RMB266.5 million or 76.8%, from RMB347.0 million for the year ended December 31, 2024, to RMB80.4 million for the year ended December 31, 2025. The adjusted loss for the period was arrived at by adjusting the IFRS profit/(loss) for the Reporting Period of RMB14.8 million (for the year ended December 31, 2024: loss of RMB442.6 million) through excluding the effect of share-based payment expenses, written-off of right-of-use assets and gain/(loss) on lease termination. Please refer to the section headed "Non-IFRS Measures" of this announcement for details.

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

Year ended December 31, 2025

	Notes	**2025** ***RMB'000***	2024 *RMB'000*
REVENUE	*4*	**49,983**	85,103
Cost of sales		**(12,658)**	(30,800)
Gross profit		**37,325**	54,303
Other income and gains/(losses), net	*5*	**109,705**	(5,533)
Selling and distribution expenses		**(47,403)**	(74,895)
Administrative expenses		**(36,799)**	(68,160)
Research and development expenses		**(45,051)**	(251,763)
Finance costs	*7*	**(2,230)**	(8,584)
Written-off of right-of-use assets		**(729)**	(87,987)
PROFIT/(LOSS) BEFORE TAX	*6*	**14,818**	(442,619)
Taxation	*8*	**–**	–
PROFIT/(LOSS) FOR THE YEAR		**14,818**	(442,619)
OTHER COMPREHENSIVE INCOME/(EXPENSES)			
Other comprehensive income/(expenses) that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of foreign operations, net		**2,546**	(65,712)
Other comprehensive income/(expenses) that will not be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of the Company		**(1,348)**	65,903
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX		**1,198**	191
TOTAL COMPREHENSIVE INCOME/(EXPENSE) FOR THE YEAR ATTRIBUTABLE TO OWNERS OF THE COMPANY		**16,016**	(442,428)
EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY			
– Basic (RMB per share)	*10*	**0.03**	(1.04)
– Diluted (RMB per share)	*10*	**0.03**	(1.04)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

December 31, 2025

	Notes	**December 31, 2025**	December 31, 2024
		RMB'000	*RMB'000*
NON-CURRENT ASSETS			
Property, plant and equipment		**136**	952
Right-of-use assets		**375**	2,687
Intangible assets		**54,712**	67,822
Total non-current assets		**55,223**	71,461
CURRENT ASSETS			
Inventories		**20,569**	7,903
Trade receivables	*11*	**15,119**	16,723
Prepayments and other receivables		**7,855**	10,224
Cash and bank balances		**66,625**	10,502
Total current assets		**110,168**	45,352
CURRENT LIABILITIES			
Trade payables	*12*	**368,834**	370,458
Other payables and accruals		**75,842**	85,066
Contract liabilities		**2,727**	-
Interest-bearing bank and other borrowings		**7,025**	15,327
Lease liabilities		**913**	11,759
Total current liabilities		**455,341**	482,610
NET CURRENT LIABILITIES		**(345,173)**	(437,258)
TOTAL ASSETS LESS CURRENT LIABILITIES		**(289,950)**	(365,797)

	Notes	**December 31, 2025**	December 31, 2024
		RMB'000	*RMB'000*
NON-CURRENT LIABILITIES			
Contract liabilities		**43,661**	-
Interest-bearing bank and other borrowings		**8,000**	15,042
Lease liabilities		**144**	93,649
Total non-current liabilities		**51,805**	108,691
Net liabilities		**(341,755)**	(474,488)
EQUITY			
Share capital		**34**	28
Reserves		**(341,789)**	(474,516)
Total deficit		**(341,755)**	(474,488)

1. GENERAL INFORMATION

The Company was incorporated as an exempted company with limited liability in the Cayman Islands on January 30, 2018. The addresses of the registered office and principal place of business of the Company are disclosed in the "Corporate Information Section" to the annual report.

The Company is an investment holding company. The Group was principally engaged in the research and development and commercialisation of medical products. The activities of its principal subsidiaries are set out in Note 38 to the consolidated financial statements.

The shares of the Company have been listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") effective from December 10, 2021.

The financial statements are presented in Renminbi ("RMB"), which is the currency of the primary economic environment in which the major entities of the Group operate. The functional currency of the Company is US dollar.

2. BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

Basis of preparation of consolidated financial statements

The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("Listing Rules") and by the disclosure requirements of the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2 Share-based Payment, leasing transactions that are accounted for in accordance with IFRS 16 Leases and measurements that have some similarities to fair value but are not fair value, such as net realisable value in IAS 2 Inventories or value in use in IAS 36 Impairment of Assets. In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;

- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and

- Level 3 inputs are unobservable inputs for the asset or liability.

Going concern assessment

The consolidated financial statements have been prepared on the assumption that the Group will continue as a going concern, which assumes that the Group will be able to meet its obligations and continue its operations for the next twelve months after December 31, 2025 notwithstanding that as at December 31, 2025, the Group had net current liabilities and net liabilities of approximately RMB345,173,000 and RMB341,755,000 respectively. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern.

In view of these circumstances, the Directors of the Company have given careful consideration to the future liquidity and performance of the Group and its available sources of financing in assessing whether the Group will have sufficient financial resources to continue as a going concern. Certain measures have been and will continue to be taken to mitigate the liquidity pressure and to improve the Group's financial position which include, but not limited to, the following:

(1) On February 16, 2026, the Company entered into the subscription agreement with WuXi Biologics HealthCare Venture (the "Subscriber"), pursuant to which the Company conditionally agreed to issue, and the Subscriber conditionally agreed to subscribe for, 84,033,613 shares in the Company at the subscription price of HK$2.38 per subscription share. The gross proceeds of the subscription amounted to approximately HK$200,000,000 and the net proceeds received by the Company under the subscription was approximately HK$199,000,000 after deducting the relevant expenses incurred in relation to the subscription. The conditions set out in the subscription agreement had been fulfilled and the subscription have been completed at March 10, 2026. For further details, please refer to the Company's announcement dated February 16, 2026 and March 10, 2026;

(2) The Group continues to monitor expenditure and take action to tighten cost controls over various operating expenses;

(3) The Group has been and will continue to actively negotiate with banks for renewal and extension of existing bank borrowings that will become due during the next twelve months after December 31, 2025. Discussions regarding the renewal and extension of existing bank borrowings as well as new bank borrowings are on-going but no binding agreements have been entered into;

(4) The Group will also continue to actively negotiate with the suppliers to extend the repayment dates of the overdue payables based on amicable relationships with the suppliers;

(5) The Group has been and will continue to actively negotiate with certain third parties to license out its pipeline assets to streamline its operations further and improve liquidity position. As at the date of this report, discussions are on-going but no binding agreements have been entered into; and

(6) The Group will further improve the profitability with two commercialised products, namely Hunterase® and Livmarli® to generate cash inflow for the Group and since Gaurunning® been granted marketing approval by the National Medical Products Administration (the "NMPA") of the People's Republic of China (the "PRC") for treatment of type I and III Gaucher disease on May 15, 2025, the Company will accelerate the commercialization of Gaurunning® and enhance the profitability.

Assuming that the above-mentioned plans and measures will succeed and having reviewed the Group's cash flow projections prepared by management, which cover a period of twelve months from December 31, 2025, the Board are of the opinion that, the Group will have sufficient working capital to finance its operations and to meet its financial obligations as and when they fall due within twelve months from December 31, 2025. Accordingly, the Directors are satisfied that it is appropriate to prepare the consolidated financial statements on a going concern basis.

Notwithstanding the above, significant uncertainties exist as to whether the Group is able to achieve its plans and measures as described above and continue to operate as a going concern. Whether the Group will be able to continue as a going concern would depend upon the following:

(1) The successful and timely implementation of the plans to control costs and reduce expenditures;

(2) The successful obtaining of continuous support from the banks for provision of new bank loans and renewal and extension of existing bank borrowings;

(3) The successful negotiation with the suppliers to extend the repayment dates of overdue payables;

(4) The successful signing of binding agreement with third parties to license out certain of its products or pipelines; and

(5) The successful increase of profitability of commercialised products;

Should the Group be unable to achieve the above-mentioned plans and measures and operate as a going concern, adjustments would have to be made to write down the carrying values of the Group's assets to their recoverable amounts, to provide for any further liabilities which might arise, and to reclassify non-current assets and non-current liabilities as current assets and current liabilities, respectively. The effects of these adjustments have not been reflected in these consolidated financial statements.

3. APPLICATION OF NEW AND AMENDMENTS TO IFRSs

New and amendments to IFRSs that are mandatorily effective for the current year

In the current year, the Group has applied the following new and amendments to IFRS Accounting Standards as issued by IASB for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2025 for the preparation of the consolidated financial statements:

Amendments to IAS 21	*Lack of Exchangeability*

The application of the amendments to IFRS Accounting Standards in the current year has had no material impact on the Group's financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

New and amendments to IFRS Accounting Standards in issue but not yet effective

The Group has not early applied the following new and amendments to IFRS Accounting Standards that have been issued but are not yet effective:

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments[2]
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity[2]
Amendments to IFRS 10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[1]
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards – Volume 11[2]
IFRS 18	Presentation and Disclosure in Financial Statements[3]
Amendments to IAS 21	Translation to a Hyperinflationary Presentation Currency[3]

1 Effective for annual periods beginning on or after a date to be determined.
2 Effective for annual periods beginning on or after January 1, 2026.
3 Effective for annual periods beginning on or after January 1, 2027.

Except for the new and amendments to IFRS Accounting Standards mentioned below, the directors of the Company anticipate that the application of all other new and amendments to IFRS Accounting Standards will have no material impact on the consolidated financial statements in the foreseeable future.

IFRS 18 Presentation and Disclosure in Financial Statements

IFRS 18 Presentation and Disclosure in Financial Statements ("IFRS 18"), which sets out requirements on presentation and disclosures in financial statements, will replace IAS 1 Presentation of Financial Statements ("IAS 1"). This new IFRS Accounting Standard, while carrying forward many of the requirements in IAS 1, introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures ("MPMs") in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. In addition, some IAS 1 paragraphs have been moved to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors (the title of which will be changed to Basis of Preparation of Financial Statements upon effective of IFRS 18) and IFRS 7. Minor amendments to IAS 7 Statement of Cash Flows and IAS 33 Earnings per Share are also made.

IFRS 18, and amendments to other standards, will be effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 requires retrospective application with specific transition provisions. The application of the new standard is not expected to have significant impact on the financial performance and positions of the Group in terms of recognition and measurement. However, it is expected to affect the structure and presentation of the consolidated statement of profit or loss.

4. OPERATING SEGMENT INFORMATION AND REVENUE

For management purpose, the Group has only one reportable operating segment, which is the development, production, marketing and sale of medical products.

Geographical information

Revenue from external customers

	2025	2024
	RMB'000	*RMB'000*
Chinese Mainland	**49,924**	40,972
Other regions	**59**	44,131
Total revenue	**49,983**	85,103

The revenue information above is based on the locations of the customers.

Non-current assets

	2025	2024
	RMB'000	*RMB'000*
Chinese Mainland	**602**	3,256
Other countries/regions	**54,621**	68,205
Total non-current assets	**55,223**	71,461

The non-current asset information above is based on the locations of the assets.

Information about major customers

Revenue from customers which contributed over 10% of the Group's revenue for the years ended December 31, 2025 and 2024 is as follows:

	2025	2024
	RMB'000	*RMB'000*
Customer A	**28,886**	27,775
Customer B	**13,102**	13,157
Customer C	**N/A***	43,211
Customer D	**7,154**	–

* The corresponding revenue did not contribute over 10% of the total revenue of the Group.

Disaggregated revenue information

	2025	2024
	RMB'000	*RMB'000*
Type of goods		
Sales of medical products	**49,201**	85,103
Strategic cooperation income	**782**	–
	49,983	85,103
Timing of revenue recognition		
A point in time	**49,201**	85,103
Over-time	**782**	–
	49,983	85,103

5. OTHER INCOME AND GAINS/(LOSSES), NET

	2025	2024
	RMB'000	*RMB'000*
Other income		
Bank interest income	**372**	508
Government grants (note)	**363**	705
Total other income	**735**	1,213
Other gains/(losses), net		
Gain on lease termination, net	**101,037**	26
Bad debt recovery	**–**	118
Gain on disposal of non-current assets classified as held for sale	**–**	6,495
Foreign exchange differences, net	**8,233**	(7,041)
Impairment of property, plant and equipment	**–**	(1,420)
Loss on disposal of intangible assets	**–**	(224)
Write down of inventory	**(770)**	–
Gain/(loss) on disposal of property, plant and equipment	**1,093**	(4,067)
Other	**(623)**	(633)
Total other gains/(losses)	**108,970**	(6,746)
Total other income and gains/(losses)	**109,705**	(5,533)

note: Government grants have been received from the PRC local government authorities to support the subsidiaries' research and development activities and other operation activities. There are no unfulfilled conditions related to these government grants.

6. PROFIT/(LOSS) BEFORE TAX

Profit/(loss) before tax has been arrived at after charging:

	2025	2024
	RMB'000	*RMB'000*
Employee benefit expenses (excluding directors' and chief executive's remuneration):		
Wages, salaries, bonus and welfare	**33,689**	75,791
Pension scheme contributions	**5,539**	4,142
Staff welfare expenses	**1,459**	3,098
Share-based payment expenses	**4,112**	6,014
	44,799	89,045
Auditors' remuneration	**1,660**	1,660
Cost of inventories sold	**12,658**	30,800
Research and development costs (excluded related employee benefit expenses, depreciation and amortisation)	**32,625**	215,603
Depreciation of property, plant and equipment	**684**	3,026
Depreciation of right-of-use assets	**1,171**	13,445
Amortisation of intangible assets	**10,293**	10,782
Short-term lease payment	**37**	345

7. FINANCE COSTS

	2025	2024
	RMB'000	*RMB'000*
Interest on bank and other borrowings	**975**	1,454
Interest on lease liabilities	**1,255**	7,130
	2,230	8,584

8. TAXATION

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

No provision of profit tax has been made in the consolidated financial statements as no assessable profit was derived from the jurisdictions in which members of the Group are domiciled and operated for both years.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, upon payments of dividends by the Company to its shareholders, no Cayman Islands withholding tax is imposed.

Hong Kong

Hong Kong profits tax has been provided at the rate of 16.5% (2024: 16.5%) on the estimated assessable profits arising in Hong Kong during the year, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HK$2,000,000 (2024: HK$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% and the remaining assessable profits are taxed at 16.5% (2024: 16.5%).

Taiwan

The subsidiary incorporated in Taiwan is subject to income tax at a rate of 20% (2024: 20%) on the estimated assessable profits arising in Taiwan during the year.

Chinese Mainland

Pursuant to the Corporate Income Tax Law of the PRC and the respective regulations (the "CIT Law"), the subsidiaries which operate in Chinese Mainland are subject to CIT at a rate of 25% (2024: 25%) on the taxable income.

United States of America

The subsidiary incorporated in Delaware, the United States was subject to statutory United States federal corporate income tax at a rate of 21% (2024: 21%) during the year.

9. DIVIDENDS

No dividends have been declared and paid by the Company for the year ended December 31, 2025 (2024: Nil).

10. EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO THE EQUITY HOLDER OF THE COMPANY

The calculation of the basic earnings/(loss) per share amounts is based on the profit/(loss) for the year attributable to the owners of the Company and the weighted average number of ordinary shares of 453,572,154 (2024: 424,829,522) in issue during the year.

For those Company's share options with an exercise price higher than the average market price of the shares, their exercise is not assumed in calculating diluted earnings/(loss) per share, as such options are anti-dilutive.

The share options granted by the Company have potential dilutive effect on the earnings per share of the Company for the year ended December 31, 2025. Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding by the assumption of the conversion of the potential dilutive ordinary shares arising from share options granted by the Company.

No adjustment has been made to the basic loss per share amounts presented for the year ended December 31, 2024 as the impact of the share options and share awards outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted earnings/(loss) per share are based on the following data:

	2025	2024
	RMB'000	*RMB'000*
Profit/(loss)		
Profit/(loss) for the purpose of basic and diluted earnings/(loss) per share	**14,818**	(442,619)
	Number of shares	
Number of shares		
Weighted average number of ordinary shares in issue	**453,572,154**	424,829,522
Effect of potential dilutive ordinary shares:		
Adjustments for grant of share options	**3,330,389**	–
Weighted average number of ordinary shares for the purpose of calculating diluted earnings/(loss) per share	**456,902,543**	424,829,522
Earnings/(loss) per share		
Basic earnings/(loss) per share (RMB)	**0.03**	(1.04)
Diluted earnings/(loss) per share (RMB)	**0.03**	(1.04)

11. TRADE RECEIVABLES

The ageing analysis of trade receivables, based on invoice dates, as at December 31, 2025 and 2024 are as follows:

	2025	2024
	RMB'000	*RMB'000*
Within 3 months	**15,119**	16,723

12. TRADE PAYABLES

The follows are an aged analysis of trade payables, presented based on the invoice dates, at the end of the reporting period.

	2025	2024
	RMB'000	*RMB'000*
Within 6 months	**90,318**	108,294
Over 6 months	**278,516**	262,164
	368,834	370,458

The trade payables are non-interest-bearing and are normally settled in less than six months or based on the specific agreement with certain suppliers.

13. COMPARATIVE

Certain comparative amounts have been reclassified to conform with current period presentation.

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Founded in 2012, CANbridge is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology. As of December 31, 2025, we have a comprehensive pipeline of 7 drug assets targeting prevalent rare diseases that have high unmet needs and significant market potential. The robust pipelines include 3 marketed products and 1 drug candidates at the late clinical stage. Given the challenging macro environment, including volatile capital markets and limited biotech funding, CANbridge has further prioritized the key programs with significant development and regulatory milestones occurring in the coming year.

We are led by a management team with significant industry experience in rare diseases, spanning R&D, clinical development, regulatory affairs, business development and commercialization. As of December 31, 2025, we have streamlined the workforce to 41 full-time employees. Our management team has a track record of successfully achieving approval and commercializing of rare disease therapies across the key markets, including Greater China and the United States (U.S). We leverage this expertise to play an active role in advancing the rare disease industry and shaping the rare disease ecosystem in China. For example, our founder, Dr. Xue, Ph.D., is currently serving as the Deputy Director General of China's Alliance for Rare Disease (CHARD).

Since our inception in 2012, we have built a comprehensive portfolio of therapeutics, consisting of biologics, small molecules and gene therapies that target diseases with validated mechanisms of action. We will continue to prioritize and optimize our pipeline through out-licensing, partnerships and collaborations with academic institutions, as well as with in-house R&D.

In the rare disease area, we have seven biologic and small molecule product candidates. These include MPS II (Hunter syndrome) and other lysosomal storage disorders (LSDs), complement-mediated disorders, hemophilia A, metabolic disorders and rare cholestatic liver diseases including ALGS and Progressive Familial Intrahepatic Cholestasis (PFIC).

- We received marketing approval for Hunterase® (CAN101) for the treatment of MPS II in mainland China in September 2020.

- We received marketing approval for Livmarli® for the treatment of ALGS in mainland China, Hong Kong and Taiwan in 2023.

- In 2024, we announced expansion of Livmarli® label to include ALGS patients as young as 3 months in mainland China, marketing approval for the treatment of cholestatic pruritus in PFIC aged 3 months and older in Taiwan and the expansion of Livmarli® label to include ALGS patients as young as 2 months in Taiwan.

- We announced a positive preliminary CAN106 Phase 1b data for a multiple ascending dose study in PNH patients in China in June 2023. Results showed promising efficacy and safety with a dose-dependent reduction of LDH levels and an increase in hemoglobin levels that demonstrate clinically meaningful hemolysis inhibition and improvement in transfusion-dependent anemia.

- In May 2025, we announced marketing approval of Gaurunning®, a class 1 new drug for treating type I and III Gaucher disease, in China.

- In December 2025, we announced inclusion of Gaurunning® (Velaglucerase-beta for Injection), a class 1 innovative drug, in China's first commercial health insurance innovative drug list.

In addition to biologics and small molecules, we are investing in next-generation technology for gene therapy. Gene therapy provides a potentially one-time, durable treatment for rare genetic diseases with limited treatment options. In November 2024, CANbridge and Scriptr announced publication in the journal Science reporting the discovery of the StitchR™ RNA assembly technology and its application for the treatment of muscular dystrophies. We continue to evaluate additional technology and pipeline opportunities, both internally and externally. These efforts are intended to support the Company's transition to a pipeline portfolio strategy focused on "First-in-Class (FIC)" and "Best-in-Class (BIC)" products and to capture value creating partnering opportunities in the future.

Market opportunities in the rare disease industry

The global rare disease industry focuses on developing medicines for diseases affecting a small number of people. Rare diseases have unique characteristics that create an efficient market for therapeutic development. Most rare diseases are caused by genetic mutations that lead to a better understanding of the disease, increasing the chance of successful R&D. Sales efforts for rare disease drugs are more targeted due to the limited number of specialists and tertiary care hospitals treating these patients. A favorable regulatory environment, like the Orphan Drug Act and expedited approval pathways in the United States, helps to accelerate the development and commercialization of rare disease drugs. In 2024, the sales of rare disease therapies surpassed 300 billion USD, and is expected to grow to 400 billion USD in 2032 (www.fiercepharma.com).

The rare disease markets in developing countries are relatively underpenetrated, due to limited access to rare disease diagnosis and treatments.

The rare disease industry in China is expected to benefit from various regulatory initiatives. China has simplified the rare disease treatment application process, streamlined the regulatory approval pathway by allowing the submission of clinical data from global trials, and is moving towards a more favorable reimbursement policy. In 2018, China released the First National List of Rare Diseases, encompassing 121 rare conditions. In 2023, the second edition of the list was unveiled, incorporating 86 additional rare diseases. With this latest update, China's rare disease catalog now encompasses a total of 207 rare conditions across both editions.

On January 17, 2025, NHSA announced 2025 NRDL adjustment to introduce a new Class C category, namely the commercial health insurance innovative drug list. It supplements existing Class A and B, covering highly innovative treatments with great clinical value but high prices. Private health insurance is crucial in selection, negotiation, coverage and payment. Class C treatments are excluded from self-pay rate assessment and some centralized procurement scopes. This indicates a multi- level funding mechanism, facilitating access to innovative treatments and reducing financial burdens.

Gene therapy is emerging as a promising therapeutic approach for rare diseases, with approximately 80% of rare diseases being genetic disorders, according to Frost & Sullivan. These therapies can address the root cause of the disease and offer curative potential. Recent advancements in genetic engineering and viral vector development have led to several approved gene therapy products.

Strategic cooperation with Baheal Medical

In August 2025, we began our strategic cooperation with Baheal Medical pursuant to which (i) we appointed certain subsidiar(ies) of Baheal Medical as our exclusive CSO for the marketing service, and, if requested by such subsidiar(ies) of Baheal Medical, as the sole distributor, for Hunterase®, Livmarli® and Gaurunning® in mainland China, Hong Kong, and Macau, from which we received a strategic engagement fee of RMB50 million; and (ii) a subsidiary of Baheal Medical subscribed 74,971,468 shares in our Company, representing 14.99% of our enlarged total number of issued shares as at the date of this announcement, under which we received a total consideration of approximately HK$100 million.

Outlook for 2026

CANbridge will continue to grow its commercial stage business in Greater China that will be significantly enhanced by the strategic partnership with Baheal Medical in mainland China. We will work diligently to introduce Gaurunning®, the first in-house developed enzyme replacement therapy for treating type I and III Gaucher Disease to international market. Our strengthened balance sheet, driven by the growing revenue and optimized cost structure as well as the strategic investment from strategic investors such as Baheal Medical and WuXi Biologics, will accelerate CANbridge's recovery and jump start the launch of our new phase of growth. We will continue to consolidate and expand our first-mover position in China rare disease market, and to explore multiple paths, including in R&D and business development to pivot the company to a more globally oriented rare disease innovator and value creator.

PIPELINE

Our Comprehensive and Diversified Pipeline

CANbridge holds global rights to 4 out of 7 assets, spanning biologics, small molecules, and gene therapy, targeting most prevalent rare diseases and oncology indications, with proven mechanisms and significant market potential.



Note: The company's early-stage pipeline includes CAN104 (Fabry disease) and CAN105 (Hemophilia A). Future development will be evaluated based on strategic priorities.

BUSINESS REVIEW

The Company was listed on the Stock Exchange on December 10, 2021. Since then, the Company has made significant progress with respect to its drug pipeline and business operations, including the following milestones and achievements.

HUNTERASE® *(idursulfase beta, formerly known as CAN101)*

- Hunterase® is the first ERT approved for the treatment of Hunter syndrome (MPS II) in China. Given that ERT is the standard of care for Hunter syndrome, and that there is currently no other drug treatment available in China, we believe there is a significant market opportunity for Hunterase®.

- CANbridge received the marketing approval from the NMPA for Hunterase® in September 2020 as the first and the only treatment for MPS II in China. Hunterase® is currently marketed in over 10 countries worldwide by GC Pharma. In a head-to-head Phase 1/2 study, Hunterase® demonstrated favorable efficacy as compared to Elaprase®, a drug commonly used to treat Hunter syndrome globally. In a Phase III clinical trial in Chinese MPS II patients, Hunterase® demonstrated favorable efficacy compared to placebo over a period of up to two years with no specific safety concerns.

- CANbridge commercially launched Hunterase® in China in May 2021 in a non-reimbursed market. Patient identification has accelerated since launch, with 893 patients identified as of December 31, 2025. As of December 31, 2025, we have implemented commercial insurance programs (Huiminbao) in 142 cities, covering a population of 626 million in China.

- The Company continues to strengthen integrated commercialization team and with the ability to commercialize multiple rare disease products.

LIVMARLI® *(maralixibat oral solution, formerly known as CAN108)*

- Livmarli® is an oral, minimally-absorbed, reversible IBAT inhibitor and is under development to treat rare cholestatic liver diseases, including ALGS (approved by FDA) and PFIC. Livmarli® possesses an extensive safety dataset, having been evaluated in more than 1,700 human subjects. Livmarli® has been studied in a number of completed and ongoing clinical trials in ALGS and PFIC with over 200 children treated and some on study for over seven years. A Phase 2b placebo-controlled randomized withdrawal period clinical trial with an open-label extension in children (aged 1-18 years) conducted for ALGS by Mirum Pharmaceuticals, Inc. ("**Mirum**"), our collaboration partner in the U.S., shows that patients receiving Livmarli® experienced significant reductions in serum bile acids and pruritus compared to placebo, improvements in quality of life and xanthomas and accelerated long-term growth. In addition, Mirum has completed a Phase 3 study of Livmarli® in PFIC, which is the largest randomized, placebo-controlled study with 93 patients across a range of genetic PFIC subtypes, including PFIC1, PFIC2, PFIC3, PFIC4, PFIC6 and unidentified mutational status. The results of this Phase 3 study demonstrated that Livmarli®-treated patients had statistically significant improvements in pruritus, serum bile acids, bilirubin and growth as measured by weight z-score in the cohort evaluating the combined genetic subtypes.

- CANbridge and Mirum have an exclusive license agreement for the development, commercialization and manufacturing, under certain conditions, of Livmarli® in Greater China.

- As of December 31 2024, Livmarli® received multiple marketing approvals for ALGS in mainland China, Hong Kong, and Taiwan, as well as approval for PFIC in Taiwan. The broad marketing approvals make Livmarli® the first and only approved product marketed for the treatment of cholestatic pruritus in patients with ALGS in these regions.

- In May 2024, we announced expansion of Livmarli® label to include patients as young as 3 months in mainland China.

- In December 2024, we announced marketing approval of Livmarli® in Taiwan for the treatment of cholestatic pruritus in PFIC patients aged 3 months and older.

- In December 2024, we announced expansion of Livmarli® label to include ALGS patients as young as 2 months in Taiwan.

- CANbridge commercially launched Livmarli® in China in January 2024 in a non-reimbursed market. Patient identification has accelerated since launch, with 900 ALGS patients identified as of December 31, 2025. As of December 31, 2025, we have implemented commercial insurance programs (Huiminbao) in 53 cities, covering a population of 260 million in China.

Gaurunning® (velaglucerase-beta for injection, formerly known as CAN103)

- Gaurunning®, a recombinant, human glucocerebrosidase (acid β-glucosidase), an ERT for the treatment of GD. CANbridge holds global proprietary rights to develop and commercialize the product.

- Gaurunning® is the first ERT for Gaucher disease in the clinical trial development stage in China.

- The first patient was dosed in the Gaurunning® Phase 1/2 trial in January 2023, which is being developed for the treatment of patients with GD Types I and III in China. Bing Han MD, Ph.D., Chief Physician and Professor in the Department of Hematology at Peking Union Medical College Hospital in Beijing, China, is the principal investigator for the trial. GD, a lysosomal storage disorder, is caused by a genetic enzyme deficiency leading to the accumulation of a cellular sphingolipid called glucocerebroside in macrophages residing in liver, spleen, and bone marrow, resulting in hepatosplenomegaly, anemia, thrombocytopenia, and skeletal disease (infarction, osteoporosis, and pain). In GD Type III, glucocerebroside also accumulates in the central nervous system, causing chronic neurodegeneration and premature death. Gaurunning® is an ERT under development by CANbridge, as part of its rare disease partnership with WuXi Biologics (Cayman) Inc. (stock code: 2269.HK), for the long-term treatment of adults and children with Gaucher disease Types I and III. Many GD patients in China do not have access to approved treatments due to cost barriers.

- In March 2025, we announced that Gaurunning®, with its wholly - owned subsidiary, CANbridge (Shanghai) Life Sciences Ltd. as the holder, successfully passed the pre-approval inspection and pre-marketing GMP compliance inspection for the pilot biological product of divided manufacturing. Gaurunning® was the first innovative biological product in China to pass the inspection of divided manufacturing of biological products.

- In May 2025, we announced marketing approval of Gaurunning®, a class 1 new drug for treating type I and III Gaucher disease, in China.

- In December 2025, we announced inclusion of Gaurunning® (Velaglucerase-beta for Injection), a class 1 innovative drug, in China's first commercial health insurance innovative drug list.

- Ongoing efforts are taken to explore partnering opportunities toward commercializing Gaurunning® outside Greater China.

CAN106 *(OMOPRUBART)*

- CAN106 is a novel, long-acting, monoclonal antibody directed against C5 complement that is being developed for the treatment of complement-mediated diseases, including PNH and MG among other approved and new potential indications. Based on clinical data, CAN106 has demonstrated a favorable PK/PD profile, safety and tolerability, indicating that CAN106 has the potential to effectively inhibit C5 in patients with PNH with a convenient four-week dosing frequency.

- CANbridge obtained global rights to develop, manufacture and commercialize CAN106 in PNH, as well as for other complement-mediated diseases that involve activation of the C5 protein, from WuXi Biologics Ireland Limited and Privus Biologics, LLC in 2019 and 2020, respectively.

- CAN106 has received Orphan Drug Designation from the FDA for the treatment of MG, an autoimmune neuromuscular disease that causes muscle weakness. CAN106 is eligible to receive the benefits provided under the Orphan Drug Act, including 50% tax credit for qualifying clinical trials, waivers for regulatory submission fees, eligibility to receive federal research grants, and upon marketing authorization for MG, 7 years of market exclusivity.

- In June 2023, CANbridge announced positive preliminary results from the ongoing Phase 1b study of CAN106 being conducted in China for PNH. The trial is being conducted under the direction of principal investigator, Dr. Bing Han, MD, PhD, Chief Physician and Professor in the Department of Hematology at Peking Union Medical College Hospital in Beijing, China. CAN106 showed dose-proportional exposure and rapid, dose-dependent reductions in free C5 levels within 24 hours, with all subjects in Cohort 3 maintaining values below 0.5 ug/mL, a historical threshold for complete C5 inhibition. CAN106 was safe and well-tolerated at all doses, and all drug-related adverse events were mild or moderate and transient, and none led to discontinuation from the study. There were no drug-related serious adverse events, and no cases of anaphylaxis or meningococcal infection. Currently, CAN106 is the only domestically-developed treatment for PNH that is actively being developed.

- Complement-mediated diseases amenable to treatment with an anti-C5 antibody remain an area of broad interest, demonstrating potential for CAN106 in multiple indications beyond PNH.

- We view CAN106 as a strong candidate in addressing multiple complement mediated diseases. CANbridge is exploring opportunities, either independently or through partnerships, with the aim to advance CAN106 to a late-stage clinical development track with substantial potential financial values.

GENE THERAPY

- In November 2024, CANbridge and Scriptr announced publication in the journal Science reporting the discovery of the StitchR™ RNA assembly technology and its application for the treatment of muscular dystrophies.

- As of December 31, 2025, we have internally generated the proof-of-concept data for DMD pre-clinical studies. CANbridge is seeking to generate further data in large animal models, with a view to ultimately advance in human studies.

WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR CORE PRODUCT CANDIDATE, OR ANY OF OUR PIPELINE PRODUCTS

Manufacturing

In March 2025, we announced that Gaurunning®, with its wholly - owned subsidiary, CANbridge (Shanghai) Life Sciences Ltd. as the holder, successfully passed the pre-approval inspection and pre-marketing GMP compliance inspection for the pilot biological product of divided manufacturing. Gaurunning® was the first innovative biological product in China to pass the inspection of divided manufacturing of biological products.

We have secured manufacturing capacity for selected in-licensed programs, including from third party collaboration partners such as WuXi Biologics, GC Pharma and Mirum. We aim to balance cost efficiency and quality control of our drug products and/or candidates. In an effort to advance our gene therapy pipelines, we are exploring manufacturing strategy for gene therapy that can help us to achieve high quality and capital efficiency anticipate to use CDMO to enable the further development of our gene therapy products.

Commercialization

In August 2025, we entered into a strategic collaboration and exclusive commercial services agreement ("**CSO Agreement**") with Beijing Baheal Zhihe Medical Achievement Transformation Service Co., Ltd. (北京百洋智合醫學成果轉化服務有限公司) ("**Baheal Zhihe**"), a subsidiary of Baheal Medical. Pursuant to such agreement, Baheal Zhihe was appointed as the exclusive CSO, and if requested by Baheal Zhihe, its affiliate will be appointed as the sole distributor, for Hunterase®, Livmarli® and Gaurunning® in mainland China, Hong Kong and Macau. At the end of 2025, we completed the transfer of promotion and distribution arrangements to Baheal, ensuring continuity and efficiency in our operational processes. CANbridge and Baheal teams continue to work collaboratively on national-level market access for all three products in mainland China. Meanwhile, in Taiwan and Hong Kong, CANbridge team is making progress toward enlisting Livmarli® and Hunterase® into the local reimbursement formularies.

With multiple products currently approved for marketing in multiple geographies, we have established our key operation hubs in Beijing, Shanghai and Suzhou, with offices in other locations in Greater China. We have set up a commercialization team dedicated to our approved products and late-stage drug candidates that can be quickly expanded in line with our business growth, comprising three major functions, including marketing and sales, medical affairs and patient advocacy assistance and market access, with the mission to execute medical engagement plans for key opinion leader (KOL) development, promote community awareness and explore industry insights for better drug development and marketing strategy.

The management continues to monitor the market to develop the most cost-effective strategy and model for commercializing these upcoming pipeline products.

KEY EVENTS AFTER THE REPORTING PERIOD

On March 10, 2026, the Company allotted and issued a total of 84,033,613 subscription shares to WuXi Biologics HealthCare Venture at the subscription price of HK$2.38 per subscription share. For details, please refer to the announcements of the Company dated February 16, 2026 and March 10, 2026.

Save as disclosed in this announcement, the Company has no key events after the Reporting Period that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**").

FINANCIAL REVIEW

Overview

The following discussion is based on, and should be read in conjunction with, the financial information and notes included elsewhere in this announcement.

Revenue

Our revenue decreased by RMB35.1 million or 41.2%, from RMB85.1 million for the year ended December 31, 2024 to RMB50.0 million for the year ended December 31, 2025, which was primarily due to the cessation of Nerlynx® sales in Taiwan following the expiry of Nerlynx® distribution agreement at the end of 2024, as originally planned by the Company in 2021 for strategically focusing on rare disease. Excluding the Nerlynx® sales in Taiwan, our revenue increased by RMB9.0 million, or 22.0% as compared with the same period in 2024, which was mainly attributable to Gaurunning® sales initiation in the second half of 2025.

Cost of Sales

Our cost of sales decreased by RMB18.1 million from RMB30.8 million for the year ended December 31, 2024 to RMB12.7 million for the year ended December 31, 2025, which was primarily attributable to the decrease in costs incurred as a result of the decreased sales of commercialized products.

Gross Profit and Gross Profit Margin

Our gross profit decreased by RMB17.0 million from RMB54.3 million for the year ended December 31, 2024 to RMB37.3 million for the year ended December 31, 2025. Our gross profit margin for the year ended December 31, 2025 was 74.7% (for the year ended December 31, 2024: 63.8%).

Other Income and Gains

Our other income and gains increased by approximately RMB115.2 million, turning from a loss of RMB5.5 million for the year ended December 31, 2024 to a profit of RMB109.7 million for the year ended December 31, 2025, primarily due to a gain of RMB101.0 million arising from the US lease termination. The gain arose as the tenant, a wholly-owned subsidiary of the Company, and the US lease property's landlord entered into a termination agreement to early terminate the lease related to the US leased property on February 24, 2025 with effect from February 28, 2025. Since the right-of-use assets related to the US lease property had been fully written off as of December 31, 2024, the lease liabilities and other payables of approximately RMB97.7 million and RMB3.3 million, respectively, were derecognised and credited to profit or loss during the year ended December 31, 2025.

Selling and Distribution Expenses

Our selling and distribution expenses decreased by approximately RMB27.5 million or 36.7%, from RMB74.9 million for the year ended December 31, 2024 to RMB47.4 million for the year ended December 31, 2025. The decrease was mainly due to the elimination of Nerlynx® sales activities and related employee costs in 2025, following the termination of its distribution agreement at the end of 2024, coupled with an increase in the sales effectiveness for rare disease products during the Reporting Period.

Administrative Expenses

Our administrative expenses decreased by RMB31.4 million or 46.0%, from RMB68.2 million for the year ended December 31, 2024 to RMB36.8 million for the year ended December 31, 2025. Such decrease was primarily attributable to our efforts on the containment of employee costs and other administrative costs during the Reporting Period.

Research and Development Expenses

Our research and development expenses decreased by approximately RMB206.7 million or 82.1%, from RMB251.8 million for the year ended December 31, 2024 to RMB45.1 million for the year ended December 31, 2025, which was mainly attributable to the NDA approval of Gaurunning® in the first half of 2025, resulting in a substantial reduction in related development activities and expenditures.

	For the year ended December 31,	
Research and development expenses	**2025**	2024
	RMB'000	*RMB'000*
Staff costs	**11,728**	26,683
Testing and clinical trial expenses	**26,569**	196,859
License fees	**182**	2,332
Depreciation and amortization	**697**	9,477
Other expenses	**5,875**	16,412
Total	**45,051**	251,763

Finance Costs

Our finance costs decreased from RMB8.6 million for the year ended December 31, 2024 to RMB2.2 million for the year ended December 31, 2025. Such decrease was primarily due to the decrease of interest on lease liabilities.

Non-IFRS Measures

In addition to the Group's consolidated financial statements, which are presented in accordance with IFRSs, the Company also uses adjusted loss for the year as an additional financial measure, which is not required by, or presented in accordance with IFRSs. We present this financial measure because it is used by our management to evaluate our financial performance by eliminating the impacts of items that we do not consider indicative of our performance results. The Company believes that these adjusted measures provide additional information to investors and others, helping them to understand and evaluate our consolidated results of operations in the same manner as our management, and thus, facilitate comparisons of operating performance from period to period and company to company to the extent applicable.

We define adjusted loss for the year as profit/(loss) for the year excluding the effect of share-based payment expenses, written-off of right-of-use assets and the gain on the lease termination. The term adjusted profit/loss for the year is not defined under the IFRSs. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, the Group's results of operations or financial condition as reported under IFRSs.

The table below sets forth a reconciliation of the adjusted loss for the year during the years indicated:

	For the year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Profit/(Loss) for the year	**14,818**	(442,619)
Add:		
Written-off of right-of-use assets	**729**	87,987
Share-based payment expenses	**5,068**	7,689
Less:		
Gain on lease termination, net	**(101,037)**	(26)
Adjusted loss for the year	**(80,422)**	(346,969)

Capital Management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximise Shareholders' value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. There is no material seasonality of borrowing requirements for the Group.

Liquidity and Financial Resources

Our cash and bank balances as of December 31, 2025 were RMB66.6 million, of which RMB3.5 million, RMB58.9 million, RMB4.0 million and RMB0.2 million, were denominated in RMB, USD, HKD and TWD, respectively. As compared to RMB10.5 million as of December 31, 2024, the increase of cash and bank balances was primarily attributable to financing from subscription. Our primary uses of cash are fund research and development effort and working capital and for other general corporate purpose.

Funding and Treasury Policy

The Group adopts a prudent funding and treasury policy, aiming to maintain an optimal financial position and minimal financial risks. The Group regularly reviews its funding requirements to maintain adequate financial resources in order to support its business operations as well as its research and development, business operation and expansion plans. For the year ended December 31, 2025, we funded our operations primarily through revenue generated from sales of commercialized products, net proceeds of subscription price received by the Company during the Reporting Period and debt financing. We closely monitor the uses of cash and cash equivalents to ensure that our financial resources have been used in the most cost-effective and efficient way. We also consider and endeavour to seek various funding sources depending on the Group's funding needs.

Bank Loans and Other Borrowings

Our bank loans and other borrowings as of December 31, 2025 were RMB15.0 million (December 31, 2024: RMB30.4 million), which were all denominated in RMB, carried fixed nominal interest rates ranging from 3.4% to 3.8% per annum.

Current ratio

Current ratio (calculated by current assets divided by current liabilities) of the Group as at December 31, 2025 was 24.2% (December 31, 2024: 9.4%). The increase in current ratio was primarily due to increase in cash and bank balance.

Gearing ratio

The gearing ratio (calculated by total interest-bearing borrowings divided by total assets) of the Group as at December 31, 2025 was 9.1% (December 31, 2024: 26.0%).

Foreign Currency Risk

We have transactional currency exposures. Certain of our cash and bank balances, trade receivables and other receivables and trade and other payables are denominated in non-functional currencies and exposed to foreign currency risk.

We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Contingent Liabilities

As of December 31, 2025, we did not have any material contingent liabilities.

Capital Expenditure and Commitments

The Group's capital expenditures in the year ended December 31, 2025 were primarily related to purchase of property, plant and equipment. In the year ended December 31, 2025, the Group incurred RMB6,000 in relation to capital expenditures.

Charges on Group Assets

As of December 31, 2025, the Group did not have any charges over its assets.

Significant Investment Held

As of December 31, 2025, the Group did not have any significant investments.

Material Acquisition and Disposal of Subsidiaries, Associates and Joint Ventures

The Group did not have any material acquisitions and disposals of subsidiaries, associates and joint ventures during the Reporting Period. Save as otherwise disclosed in the Prospectus, the Group does not have any specific future plans on material investments or capital assets as of the date of this announcement.

Share Schemes

Pre-IPO Equity Incentive Plan

The Company adopted the 2019 equity incentive plan (the "**Pre-IPO Equity Incentive Plan**") on July 25, 2019 and amended it on June 11, 2021.

The maximum number of Shares that may be subject to the awards granted and sold under the Pre-IPO Equity Incentive Plan is 54,549,230 Shares and share options (including those have subsequently lapse or been fully exercised) to subscribe for 55,708,000 Shares thereof had been granted. No share options were granted under the Pre-IPO Equity Incentive Plan after the Company's listing.

During the Reporting Period, 510,000 options were exercised, and 7,368,423 options lapsed. As at December 31, 2025, the Company had 21,653,760 options outstanding.

Post-IPO RSU Scheme

The Company has conditionally adopted the post-IPO RSU scheme by Shareholders' resolution dated November 18, 2021 (the "**Post-IPO RSU Scheme**"). On June 27, 2024, the Post-IPO RSU Scheme was amended and the scheme limit for the Post-IPO RSU Scheme was refreshed.

Upon refreshing the scheme limit, the maximum number of Shares which may be allotted and issued in respect of all awards in the form of restricted share units ("**RSUs**") that may be granted under the Post-IPO RSU Scheme, when aggregated with the maximum number of Shares in respect of which options or awards may be granted under any other share scheme over Shares, shall not exceed 10 per cent of the issued capital of the same class of the Company (excluding any treasury shares) as of June 27, 2024 (or of the date on which the refreshing of the 10 per cent limit is approved by the shareholders of the Company). Awards lapsed in accordance with the terms of the Post-IPO RSU Scheme shall not be counted for the purpose of calculating the scheme limit.

On or before June 27, 2024, 12,136,000 RSUs were granted under the Post-IPO RSU Scheme. During the Reporting Period, no RSUs were granted by the Company under the Post-IPO RSU Scheme.

During the Reporting Period, 581,400 RSUs were vested and exercised, and 1,511,600 lapsed. As at December 31, 2025, the Company has 4,581,750 RSUs outstanding.

Post-IPO Share Option Scheme

The Company has conditionally adopted the post-IPO share option scheme by Shareholders' resolution dated November 18, 2021 (the "**Post-IPO Share Option Scheme**"). On June 27, 2024, the Post-IPO Share Option Scheme was amended and the scheme limit for the Post-IPO Share Option Scheme was refreshed.

Upon refreshing the scheme limit, the maximum number of Shares which may be allotted and issued in respect of all options that may be granted under the Post-IPO Share Option Scheme, when aggregated with the maximum number of Shares in respect of which options or awards may be granted under any other share scheme over Shares, shall not exceed 10 per cent of the issued share capital of the same class of the Company (excluding any treasury shares) as of June 27, 2024 (or of the date on which the refreshing of the 10 per cent limit is approved by the shareholders of the Company). Options lapsed in accordance with the terms of the Post-IPO Share Option Scheme shall not be counted for the purpose of calculating the scheme limit.

On or before June 27, 2024, 24,685,000 Options were granted under the Post-IPO Share Option Scheme. During the Reporting Period, no share options were granted by the Company under the Post-IPO Share Option Scheme.

During the Reporting Period, 804,250 share options were exercised, and 5,020,421 share options lapsed. As at December 31, 2025, the Company has 8,749,500 share options outstanding.

Compliance with the Corporate Governance Code ("CG Code")

The Company is committed to maintaining high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability. The Company has complied and adopted the principles and the code provisions of the CG Code as set out in Appendix C1 to the Listing Rules as its own code of corporate governance.

The Board is of the view that the Company has complied with the principles and all applicable code provisions of the CG Code during the Reporting Period, save for the deviation from C.2.1 of the CG Code as disclosed below.

We have not separated the roles of the Chairman of the Board and the Chief Executive Officer. Dr. Xue has served as chairman of the board and general manager of CANbridge Life Sciences Ltd. since June 2012 and as Chairman of the Board, Director and Chief Executive Officer since the inception of our Company in January 2018. Dr. Xue is the founder of the Group and has extensive experience in the business operations and management of our Group. Our Board believes that, in view of his experience, personal profile and his roles in our Company, Dr. Xue is the Director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as our Chief Executive Officer. Our Board also believes that the combined role of Chairman of the Board and Chief Executive Officer can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board. Our Directors consider that the balance of power and authority will not be impaired due to this arrangement. In addition, all major decisions are made in consultation with members of the Board, including the relevant Board committees, and four independent non-executive Directors.

The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

Compliance with Model Code

The Company has adopted a code of conduct regarding Directors' securities transactions on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules (the "**Model Code**"). Specific enquiries have been made to all the Directors and they have confirmed that they have complied with the Model Code during the year ended December 31, 2025.

Purchase, Sale or Redemption of the Company's Listed Securities

During the Reporting Period, neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities (including sale of treasury shares (as defined under the Listing Rules). As at December 31, 2025, the Company did not hold any treasury shares.

Employee and Remuneration Policy

As at December 31, 2025, the Group had 41 employees (2024: 67). The Group's employees' remuneration consists of salaries, bonuses, share-based incentive plans, an employees' provident fund, and social security contributions and other welfare payments. In accordance with applicable laws in relevant jurisdictions, we have made contributions to social security insurance funds (including pension plans, unemployment insurance, work-related injury insurance, medical insurance and maternity insurance) and housing funds for the employees of the Group.

We conduct new staff training regularly to guide new employees and help them adapt to the new working environment. In addition, we provide on-line and in-person formal and comprehensive company-level and department-level training to our employees periodically in addition to on-the-job training. We also encourage our employees to attend external seminars and workshops to enrich their technical knowledge and develop competencies and skills.

During the Reporting Period, the total staff costs (including Director's emoluments) were approximately RMB50.4 million (2024: RMB97.4 million).

FINAL DIVIDEND

The Board has resolved not to recommend the payment of a final dividend for the year ended December 31, 2025 (2024: nil). The Company is taking measures to generate more revenue in commercializing the Group's products and monetizing the Group's pipeline through licensing out. If the Company generates profit as a result of increase in revenue, the Board will consider distributing dividend in compliance with applicable laws and regulations.

ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS

Further announcement(s) will be made by the Company in respect of the proposed date on which the forthcoming annual general meeting will be held and the period during which the register of members of the Company will be closed in order to ascertain Shareholders' eligibility to attend and vote at the said meeting.

SCOPE OF WORK OF HLB

The financial information in respect of the announcement of the Group's results for the year ended December 31, 2025 have been agreed by the Group's auditors, HLB, to the amounts set out in the Group's consolidated financial statements for the year. The work performed by HLB in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by HLB on the results announcement.

EXTRACT OF THE AUDITOR'S REPORT

The following is the extract of the independent auditor's report on the Company's consolidated financial statements for the year ended December 31, 2025:

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("**HKSAs**") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants (the "**Code**"), as applicable to audits of financial statements of public interest entities, and we have also fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

We draw attention to Note 2 to the consolidated financial statements, which indicates that as at December 31, 2025, the Group had net current liabilities and net liabilities of RMB345,173,000 and RMB341,755,000 respectively. These conditions, along with other matters as set forth in Note 2 to the consolidated financial statements, indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

AUDIT COMMITTEE REVIEW OF FINANCIAL STATEMENTS

The Audit Committee has considered and reviewed the audited consolidated annual results of the Group for the year ended December 31, 2025 and the accounting principles and practices adopted by the Group, and has discussed with management on issues in relation to internal control, risk management and financial reporting. The Audit Committee is of the opinion that the audited consolidated annual results of the Group for the year ended December 31, 2025 are in compliance with the relevant accounting standards, laws and regulations.

PUBLICATION OF ANNUAL RESULTS AND ANNUAL REPORT

This annual results announcement of the Company is published on the Company's website (www.canbridgepharma.com) and the website of the Stock Exchange (www.hkexnews.hk).

The 2025 annual report of the Company containing all relevant information required under the Listing Rules will be despatched to the shareholders of the Company (if requested), and will be published on the aforementioned websites in April 2026.

By order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, March 30, 2026

As at the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei and Mr. Wang Tingwei as non-executive Directors, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.